Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

About IMD

In this section

The Investigative Medicine Division houses the Translational Immune Discovery Unit (TIDU).

Hands working in a wet lab at a bench

Abnormalities in immunity impact on most if not all diseases. The TIDU brings together 15 immunology groups and over 130 researchers defining the principles governing immune system function in health and utilising these insights to re-define immune disease pathogenesis. We innovate our findings to generate new medicines for patients.

The Investigative Medicine Division also supports groups in wider RDM including stroke medicine.

The MRC Translational Immune Discovery Unit (TIDU) works at the frontiers of human molecular immunology defining mechanisms of innate and adaptive immunity of relevance for immune disease pathogenesis. We apply state of the art technical and multidisciplinary approaches to tackle the major unknowns in immune function and use this information to develop new methods to harness immunity for life-long health.

Professor Alison Simmons is the Head of Investigative Medicine.

Head of Investigative Medicine

Latest publications

More publications